{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060219","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.966860+00:00","generated_at":"2026-06-08T15:51:49.180622+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Crinetics reports Q3 net loss of $57.5M; Phase 3 acromegaly study met all endpoints","bullets":["Phase 3 PATHFNDR-1: 83% paltusotine vs 4% placebo maintained IGF-1 ≤1xULN (p<0.0001); all secondary endpoints met.","Phase 3 PATHFNDR-2 enrollment completed (112 participants); topline data expected Q1 2024.","Initial Phase 2 data for paltusotine in carcinoid syndrome expected December 2023; NDA submission planned for 2024.","Net loss $57.5M vs $41.9M YoY; R&D expenses $43.8M (up $11.8M); G&A $15.5M (up $3.6M).","Cash $554.7M as of Sep 30, 2023; $350M public offering completed; cash runway into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060219","json":"https://secwatch.observer/filing/0000950170-23-060219.json","markdown":"https://secwatch.observer/filing/0000950170-23-060219.md","text":"https://secwatch.observer/filing/0000950170-23-060219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023060219/0000950170-23-060219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023060219/crnx-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:51:49.180622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1178e843c27deec0daf2fae48aaf71edbc02021c","claim":"Crinetics Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: revenue $0.3 million, net income $57.5 million.","evidence_excerpt":"$3.2 million. • Net loss for the three months ended September 30, 2023, was $57.5 million, compared to a net loss of $41.9 million for the same period in 2022. • Revenues were $0.3 million for the three months ended September 30, 2023, compared to $0.5 million for the same period in 2022. Revenues in both periods were primarily derived from the paltusotine","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023060219/0000950170-23-060219-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$0.3 million"},{"label":"Net income","value":"$57.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}